| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | ARSG |
| Uniprot No | Q96EG1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 17-525aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSGFLYPLV DFCISGKTRG QKPNFVIILA DDMGWGDLGA NWAETKDTAN LDKMASEGMR FVDFHAAAST CSPSRASLLT GRLGLRNGVT RNFAVTSVGG LPLNETTLAE VLQQAGYVTG IIGKWHLGHH GSYHPNFRGF DYYFGIPYSH DMGCTDTPGY NHPPCPACPQ GDGPSRNLQR DCYTDVALPL YENLNIVEQP VNLSSLAQKY AEKATQFIQR ASTSGRPFLL YVALAHMHVP LPVTQLPAAP RGRSLYGAGL WEMDSLVGQI KDKVDHTVKE NTFLWFTGDN GPWAQKCELA GSVGPFTGFW QTRQGGSPAK QTTWEGGHRV PALAYWPGRV PVNVTSTALL SVLDIFPTVV ALAQASLPQG RRFDGVDVSE VLFGRSQPGH RVLFHPNSGA AGEFGALQTV RLERYKAFYI TGGARACDGS TGPELQHKFP LIFNLEDDTA EAVPLERGGA EYQAVLPEVR KVLADVLQDI ANDNISSADY TQDPSVTPCC NPYQIACRCQ AA |
| 预测分子量 | 57 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ARSG(假设为Arylsulfatase G)重组蛋白的模拟参考文献示例，供参考：
---
1. **文献名称**: *"Expression and Purification of Recombinant Human Arylsulfatase G in Mammalian Cells"*
**作者**: Smith, J. et al.
**摘要**: 本研究利用HEK293细胞系统表达重组人源ARSG蛋白，优化了其分泌表达条件，并通过亲和层析和离子交换层析实现高纯度制备。实验表明重组ARSG具有硫酸酯酶活性，为酶替代疗法的开发奠定了基础。
2. **文献名称**: *"Structural and Functional Characterization of Recombinant ARSG: Insights into Substrate Specificity"*
**作者**: Zhang, L. et al.
**摘要**: 通过X射线晶体学解析重组ARSG的三维结构，结合酶动力学分析，揭示了其底物结合口袋的关键残基，并证明其对硫酸酯多糖的特异性降解作用，为溶酶体贮积症的治疗提供分子机制支持。
3. **文献名称**: *"Recombinant ARSG as a Therapeutic Agent in a Mouse Model of Metachromatic Leukodystrophy"*
**作者**: Johnson, R. et al.
**摘要**: 在小鼠模型中评估重组ARSG的疗效，结果显示静脉注射后酶活性在脑组织中显著升高，神经退行性病变得到缓解，证实其跨血脑屏障潜力及治疗可行性。
4. **文献名称**: *"Optimization of Recombinant ARSG Production in Pichia pastoris for Industrial-scale Applications"*
**作者**: Lee, H. et al.
**摘要**: 在毕赤酵母系统中开发ARSG的高效分泌表达策略，通过发酵条件优化使产量提高10倍，并验证其稳定性与生物活性，为大规模生产提供经济可行的方案。
---
**注意**：以上文献为模拟示例，实际引用需根据具体研究检索真实数据库(如PubMed、Web of Science)。若ARSG指向其他含义(如特定基因或技术)，请提供更多背景以便精准推荐。
**Background of ARSG Recombinant Protein**
Arylsulfatase G (ARSG), also known as GALNS-related protein, is a lysosomal enzyme belonging to the sulfatase family. It plays a critical role in the hydrolysis of sulfate esters from glycosaminoglycans (GAGs) and other substrates within lysosomes, contributing to cellular metabolic homeostasis. ARSG shares structural and functional similarities with other sulfatases, such as arylsulfatase A (ARSA) and B (ARSB), but its specific biological roles and substrates remain under investigation.
Genetic mutations in the *ARSG* gene are linked to lysosomal storage disorders (LSDs), particularly those involving impaired GAG degradation. While ARSG deficiency has not yet been definitively associated with a named human disease, studies suggest its potential involvement in atypical forms of mucopolysaccharidoses (MPS) or other LSDs, warranting further research.
Recombinant ARSG protein is produced using biotechnological platforms, such as mammalian or insect cell expression systems, to ensure proper post-translational modifications (e.g., glycosylation) critical for enzymatic activity. This engineered protein serves as a vital tool for studying ARSG's substrate specificity, catalytic mechanisms, and role in lysosomal pathways. It also holds therapeutic potential, as recombinant sulfatases are explored in enzyme replacement therapy (ERT) for LSDs.
Current research focuses on elucidating ARSG's substrate profile, interactions with cofactors, and its contribution to lysosomal dysfunction in disease models. The development of recombinant ARSG facilitates drug discovery, diagnostic assays, and preclinical studies aimed at addressing unmet needs in rare metabolic diseases.
×
